Head-to-head · WeighScore
No BS RX vs NovoCare Pharmacy
By GLP-1 ScorecardUpdated
Score comparison
No BS RX has the higher recorded score — 82.8/100 to 55.2/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.
Before you choose
Before comparing the headline prices, the No BS RX review and the NovoCare Pharmacy review set out what each semaglutide figure in the table below covers, including whether the medication is a brand-name product billed by a pharmacy. Brand-name and compounded prices are different products, so set like against like before treating either one as cheaper.
If neither one fits, No BS RX vs NowPatient and NovoCare Pharmacy vs Rex MD compare each of them with another graded program, and the list of alternatives to No BS RX ranks the programs closest to No BS RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the System Labs review covers one graded close to these two, at 68.4/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | No BS RX | NovoCare Pharmacy |
|---|---|---|
| WeighScore | 82.8/100 | 55.2/100 |
| Grade | B− | C |
| Site position | #23 | #472 |
| Semaglutide | $149/mo advertised for standard compounded injection; low-dose priced separately | Branded Wegovy injection: $349 standard fill (4 pens / 28 days); starter, HD and tablet offers vary by dose and eligibility. |
| Tirzepatide | $225/mo advertised for standard compounded injection; low-dose priced separately | Not disclosed |
| Coverage | Confirm program availability for your state | BlinkRx network pharmacies collectively cover 50 states, DC and Puerto Rico; confirm the assigned dispenser and eligibility. |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
Strengths
- Displays monthly and prepaid amounts by program
- Advertises consultation, medication, shipping and messaging in the compounded plans
- Lists branded Ozempic and Zepbound separately
What to consider
- The $115 headline applies to low-dose programs
- Plans renew automatically at the then-current rate
- Cancellation generally stops future billing without refunding the current period
Site position #472 · C
Strengths
- Names BlinkRx and legacy pharmacy arrangements rather than leaving the fulfillment route anonymous.
- Publishes a two-fill $199 Wegovy injection starter offer with specific eligibility and prescription/shipping deadlines.
- Publishes dose-specific Wegovy tablet and injection self-pay offers for comparison.
- Advertises free home delivery powered by BlinkRx.
- Provides independent prescriber options as well as delivery and pharmacy-pickup information.
What to consider
- Reviewed offers cover branded semaglutide products, including Wegovy and Ozempic; no tirzepatide or compounded offer was established.
- A prescription is required; linked independent care does not establish included visits or follow-up.
- The medication offer does not establish an included prescriber follow-up plan or a complete selected-order refund agreement.
- Manufacturer-set pricing can change at any time
- Eligible Wegovy injection starter pricing covers two 28-day fills under the delivery offer’s December 31, 2026 prescription and January 31, 2027 shipping deadlines; standard pricing follows.
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.